secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001326190-25-000003
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune appoints former Dexcom CCO Teri Lawver and ex-Intercept CEO Jerry Durso to board
--------------------------------------------------------------------------------

- Board expanded by two to ten; Lawver and Durso appointed effective Feb 24, 2025.
- Lawver, former Dexcom EVP/CCO and J&J Worldwide VP Immunology, brings 30 years pharma/commercial experience.
- Durso, ex-CEO of Intercept Pharmaceuticals and 22-year Sanofi vet, led rare liver disease franchise and acquisition.
- Each director received initial option for 69,800 shares and $40,000 annual cash retainer.
- Appointments support late-stage development and pre-commercial transition for pemvidutide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000003/0001326190-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000003/alt-20250224x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer